Journal Information
Vol. 5. Issue 2.
Pages 66-70 (March - April 2009)
Share
Share
Download PDF
More article options
Vol. 5. Issue 2.
Pages 66-70 (March - April 2009)
Full text access
A comparison of leflunomide and subcutaneous methotrexate in the treatment of rheumatoid arthritis: an approximation based on the number needed to treat
Comparación de leflunomida y metrotrexato subcutáneo en el tratamiento de la artritis reumatoide: una aproximación basada en el número de pacientes que es necesario tratar
Visits
5731
Antonio J. Garcia Ruiza,
Corresponding author
ajgr@uma.es

Corresponding author.
, Ana C. Montesinos Galveza, Lucia Perez Costillasa, Pablo Rebollob
a Unit of Pharmacoeconomics and Health Results Research, Universidad de Málaga, Málaga, Spain
b BAP Health Outcomes, Oviedo, Spain
This item has received
Article information
Abstract
Objective

To compare, in the Spanish setting, 2 drugs for adults with rheumatoid artritis (RA): leflunomide and subcutaneous methotrexate (SC). The high price of methotrexate SC compared with traditional presentations of methotrexate justifies conducting an economic evaluation comparing it with leflunomide.

Methods

The analysis considered the annual costs of the drugs and their effectiveness, measured with a number needed to treat (NNT) approach, considering both the ACR20 and ACR50 criteria for effectiveness. Data about efficacy and dosage were derived from the clinical trial US310, a randomized, doble-blinded controlled trial, which compared efficacy and safety of leflunomide (20mg/daily) versus placebo versus methotrexate (7.5–15mg/weekly) in 482 patients with active RA. Data about use of medical resources for drug monitoring (visits to rheumatologists and diagnostic procedures) were derived from the manufacturers¿ summary of product characteristics. Direct costs (drugs and monitoring) were obtained from 2 Spanish databases. The analysis has been performed under the Spanish National Health System perspective.

Results

Using the ACR20 criteria, the NNT with leflunomide and methotrexate are 4 (95% CI, 2.56–7.71) and 5 (95% CI, 3.03–14.3) respectively. Using the ACR50 criteria, NNT are 4 (95% CI, 2.72-6.54) and 7 (95% CI, 4.03–19.3). In the case of leflunomide, annual treatment costs per patient-year equals €1793.30; in the case of methotrexate total treatment costs amounts to €2149.20

Conclusions

Combining these results the cost of a controlled patient according to ACR20 would amount €7173 for leflunomide and €10 746 for methotrexate SC. Results considering ACR50 are €7173 and €15 044 for leflunomide and methotrexate respectively.

Keywords:
Rheumatoid arthritis
Treatment
Cost
NNT
Pharmacoeconomics
Resumen
Objetivo

Comparar 2 farmacos para la artritis reumatoide (AR): leflunomida y metotrexato subcutaneo (s.c.) (jeringas precargadas), considerando tanto costes anuales de tratamiento como la efectividad medida a traves del numero de pacientes que es necesario tratar (NNT).

Métodos

Los datos de eficacia y dosis fueron extraidos del ensayo clinico US310, ensayo aleatorizado y doble ciego, que tuvo por objetivo comparar la eficacia y la seguridad del tratamiento a 12 meses con leflunomida (20mg/dia) frente a placebo y metotrexato (7,5–15mg/semana) en 482 pacientes con AR activa. La informacion sobre los actos medicos para los seguimientos de control se obtuvo de la ficha tecnica del producto. El estudio de costes se ha realizado con la perspectiva del Sistema Nacional de Salud espanol.

Resultados

Considerando el criterio de ACR20, el NNT de leflunomida es 4 (intervalo de confianza [IC] del 95%, 2,56-7,71) y el de metotrexato s.c., 5 (IC del 95%, 3,03–14,3); para el criterio de ACR50, el NNT de leflunomida es 4 (IC del 95%, 2,72–6,54) y el de metotrexato s.c., 7 (IC del 95%, 4,03–19,3). El coste anual del farmaco fue 1.112,52 euros para la leflunomida y 1.438,91 euros para el metotrexato s.c. Los costes anuales de monitorizacion fueron 680,76 euros para la leflunomida y 710,26 euros para el metotrexato s.c.

Conclusiones

Combinando la informacion, el coste de un paciente respondedor segun ACR20 seria de 7.173 euros con leflunomida y 10.746 euros con metotrexato s.c.; los resultados considerando ACR50 oscilarian entre los 7.173 euros para la leflunomida y 15.044 euros para el metotrexato s.c.

Palabras clave:
Artritis reumatoide
Tratamiento
Costes
NNT
Farmacoeconomía
Full text is only aviable in PDF
References
[1.]
L. Carmona, V. Villaverde, C. Hernandez, J. Ballina, R. Gabriel, A. Laffon.
The prevalence of rheumatoid arthritis in the general population of Spain.
Rheumatology, 41 (2002), pp. 88-95
[2.]
L. Carmona.
Epidemiologia de la artritis reumatoide.
Rev Esp Reumatol, 29 (2002), pp. 86-89
[3.]
N. Gomez Rodriguez.
Repercusion socioeconomica de la artritis reumatoide.
An Med Interna (Madrid), 20 (2003), pp. 111-113
[4.]
V. Strand, S. Cohen, M. Schiff, A. Weaver, R. Fleischmann, G. Cannon.
Treatment of active rheumatoid artritis with leflunomide compared with placebo and methotrexate.
Arch Intern Med, 159 (1999), pp. 2542-2550
[5.]
D.T. Felson, J.J. Anderson, M. Boers, C. Bombardier, D. Furst, C. Godsmith.
American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis.
Arthritis Rheum, 38 (1995), pp. 727-735
[6.]
P. Emery, F.C. Breedveld, E.M. Lemmel, J.P. Kaltwasser, P.T. Dawes, B. Gomor.
A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis.
Rheumatology, 39 (2000), pp. 655-665
[7.]
Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B. Comite de Especialidades farmaceuticas. Informe europeo publico de evaluacion (EPAR) [cited Feb 8, 2007]. London: EMEA. Available from: http://www.emea.eu.int/humandocs/PDFs/EPAR/Arava/169499es1.pdf
[8.]
P.K. Schadlich, H. Zeidler, A. Zink, E. Grommica-Ihle, M. Schneider, C. Straub.
Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for Rheumatoid Arthritis in Germany.
Pharmacoeconomics, 23 (2005), pp. 395-420
[9.]
J. Wegrzyn, P. Adeleine, P. Miossec.
Better efficacy of methotrexate given by intramuscular injection than orally in patients with rheumatoid arthritis.
Ann Rheum Dis, 63 (2004), pp. 1232-1234
[10.]
R.K. Moitra, J.M. Ledingham, R.G. Hull, F.C. McCrae, A.L. Thomas, R. Shaban.
Caveats to the use of parenteral methotrexate in the treatment of rheumatic disease.
Rheumatology, 44 (2005), pp. 256-257
[11.]
S.J. Bingham, M.H. Buch, S. Lindsay, A. Pollard, J. White, P. Emery.
Parenteral methotrexate should be given before biological therapy.
Rheumatology, 42 (2003), pp. 1009-1010
[12.]
V. Abraira.
Medidas del efecto de un tratamiento (II): odds ratio y numero necesario para tratar.
SEMERGEN, 27 (2001), pp. 418-420
[13.]
Abraira V. Fichas tecnicas de Producto: Ministerio de Sanidad y Consumo (Madrid) [cited Feb 8, 2007]. Available from: http://www.agemed.es/
[14.]
Abraira V. Vademecum Internacional (epub publication) [cited Feb 8, 2007]. Madrid: CMP MEDICOM; 2007. Available from: http://www.vademecum.es/
[15.]
Abraira V. Base de Datos de Costes Sanitarios eSalud (epub publicationen) [cited Feb 8, 2007]. Barcelona: Oblikue Consukting. Available from: http://www.oblikue.com/bddcostes/
[16.]
G. Kobelt, P. Lindgren, A. Young.
Modelling the costs and effects of leflunomide in rheumatoid arthritis.
Eur J Health Econom, 3 (2002), pp. 180-187
[17.]
J.S. Smolen, J.R. Kalden, D.L. Scott, B. Rozman, T.K. Kvien, A. Larsen.
Efficacy and safety of leflunomide compared with placebo and sulphasalazine in activa rheumatoid arthritis: a double-blind, randomised, multicentre trial.
Lancet, 23 (1999), pp. 259-266
[18.]
V. Strand, P. Tugwell, C. Bombardier, A. Maetzel, B. Crawford, C. Dorrier.
Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis.
[19.]
C. Rubio-Terres, A. Dominguez-Gil.
Pharmacoeconomic analysis of the treatment of rheumatoid arthritis with Leflunomide in comparison of Infliximab and Methotrexate.
J Med Economics, 4 (2001), pp. 19-34
[20.]
J. Braun, P. Kastner, P. Flaxenberg, J. Wahrisch, P. Hanke, W. Demary.
Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial.
Arthritis Rheum, 58 (2008), pp. 73-81
[21.]
S. Kose, A. Mandiracioglu.
Fear of blood/injection in healthy and unhealthy adults admitted to a teaching hospital.
Int J Clin Pract, 61 (2007), pp. 453-457
Copyright © 2009. Sociedad Española de Reumatología and Colegio Mexicano de Reumatología
Idiomas
Reumatología Clínica (English Edition)
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?